Physician profile
Gina Askar
NPI 1376168468
$1,264.61
in general payments reported to CMS, 2019-2025
14 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.20 · 2022: $192 · 2023: $349 · 2024: $375 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $475.51 | 2021-2025 | Dovato, Cabenuva, Rukobia |
| Abbvie INC. | $207.57 | 2022-2025 | Avycaz, Teflaro, Dalvance |
| Merck Sharp & Dohme LLC | $164.55 | 2021-2024 | Delstrigo, Pifeltro, Dificid |
| Melinta Therapeutics, LLC | $89.55 | 2022-2025 | Rezzayo, Vabomere |
| Astellas Pharma US INC | $57.34 | 2025 | Cresemba |
| Shionogi INC | $51.88 | 2023-2024 | Fetroja |
| La Jolla Pharmaceutical Company | $42.25 | 2023-2025 | Xacduro, Xerava |
| Paratek Pharmaceuticals, INC. | $39.58 | 2024-2025 | Nuzyra |
| Janssen Biotech, INC. | $35.82 | 2022-2023 | Symtuza |
| Gilead Sciences, INC. | $30.08 | 2023 | Veklury, Epclusa |
| Theratechnologies INC. | $25.37 | 2022 | |
| Insmed, INC. | $17.32 | 2023 | Arikayce |
| Janssen Scientific Affairs, LLC | $14.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Askar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.